PVLA PE Ratio & Valuation, Is PVLA Overvalued

Historical Valuation

Palvella Therapeutics Inc (PVLA) is now in the Fair zone, suggesting that its current forward PS ratio of 53466.81 is considered Fairly compared with the five-year average of -13.02. The fair price of Palvella Therapeutics Inc (PVLA) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：138.77

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Palvella Therapeutics Inc (PVLA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Palvella Therapeutics Inc (PVLA) has a current Price-to-Book (P/B) ratio of 28.75. Compared to its 3-year average P/B ratio of 10.56, the current P/B ratio is approximately 172.15% higher. Relative to its 5-year average P/B ratio of 10.56, the current P/B ratio is about 172.15% higher. Palvella Therapeutics Inc (PVLA) has a Forward Free Cash Flow (FCF) yield of approximately -2.15%. Compared to its 3-year average FCF yield of -4.06%, the current FCF yield is approximately -47.15% lower. Relative to its 5-year average FCF yield of -4.06%, the current FCF yield is about -47.15% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PVLA competitors is 8965.27, providing a benchmark for relative valuation. Palvella Therapeutics Inc Corp (PVLA.O) exhibits a P/S ratio of 53466.81, which is 496.38% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PVLA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PVLA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PVLA currently overvalued or undervalued?

What is Palvella Therapeutics Inc (PVLA) fair value?

PVLA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Palvella Therapeutics Inc (PVLA) is between to according to relative valuation method.

How does PVLA's valuation metrics compare to the industry average?

The average P/S ratio for PVLA's competitors is 8965.27, providing a benchmark for relative valuation. Palvella Therapeutics Inc Corp (PVLA) exhibits a P/S ratio of 53466.81, which is 496.38% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Palvella Therapeutics Inc (PVLA) as of Mar 11 2026?

As of Mar 11 2026, Palvella Therapeutics Inc (PVLA) has a P/B ratio of 28.75. This indicates that the market values PVLA at 28.75 times its book value.

What is the current FCF Yield for Palvella Therapeutics Inc (PVLA) as of Mar 11 2026?

As of Mar 11 2026, Palvella Therapeutics Inc (PVLA) has a FCF Yield of -2.15%. This means that for every dollar of Palvella Therapeutics Inc's market capitalization, the company generates -2.15 cents in free cash flow.

What is the current Forward P/E ratio for Palvella Therapeutics Inc (PVLA) as of Mar 11 2026?

As of Mar 11 2026, Palvella Therapeutics Inc (PVLA) has a Forward P/E ratio of -25.63. This means the market is willing to pay $-25.63 for every dollar of Palvella Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Palvella Therapeutics Inc (PVLA) as of Mar 11 2026?

As of Mar 11 2026, Palvella Therapeutics Inc (PVLA) has a Forward P/S ratio of 53466.81. This means the market is valuing PVLA at $53466.81 for every dollar of expected revenue over the next 12 months.

PVLA Valuation